» Articles » PMID: 28992139

Concentrations of Representative Uraemic Toxins in a Healthy Versus Non-dialysis Chronic Kidney Disease Paediatric Population

Overview
Date 2017 Oct 10
PMID 28992139
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic kidney disease (CKD) in childhood is poorly explained by routine markers (e.g. urea and creatinine) and is better depicted in adults by other uraemic toxins. This study describes concentrations of representative uraemic toxins in non-dialysis CKD versus healthy children.

Methods: In 50 healthy children and 57 children with CKD Stages 1-5 [median estimated glomerular filtration rate 48 (25th-75th percentile 24-71) mL/min/1.73 m2; none on dialysis], serum concentrations of small solutes [symmetric and asymmetric dimethyl-arginine (SDMA and ADMA, respectively)], middle molecules [β2-microglobuline (β2M), complement factor D (CfD)] and protein-bound solutes [p-cresylglucuronide (pCG), hippuric acid (HA), indole-acetic acid (IAA), indoxyl sulphate (IxS), p-cresyl sulphate (pCS) and 3-carboxy-4-methyl-5-propyl-furanpropionic acid (CMPF)] were measured. Concentrations in the CKD group were expressed as z-score relative to controls and matched for age and gender.

Results: SDMA, CfD, β2M, IxS, pCS, IAA, CMPF and HA concentrations were higher in the overall CKD group compared with controls, ranging from 1.7 standard deviations (SD) for IAA and HA to 11.1 SD for SDMA. SDMA, CfD, β2M, IxS and CMPF in CKD Stages 1-2 with concentrations 4.8, 2.8, 4.5, 1.9 and 1.6 SD higher, respectively. In contrast, pCS, pCG and IAA concentrations were only higher than controls from CKD Stages 3-4 onwards, but only in CKD Stage 5 for ADMA and HA (z-score 2.6 and 20.2, respectively).

Conclusions: This is the first study to establish reference values for a wide range of uraemic toxins in non-dialysis CKD and healthy children. We observed an accumulation of multiple uraemic toxins, each with a particular retention profile according to the different CKD stages.

Citing Articles

Gut-derived metabolites as treatment targets in chronic kidney disease-an avenue toward personalized medicine.

Holle J, Bartolomaeus H Pediatr Nephrol. 2025; .

PMID: 39820506 DOI: 10.1007/s00467-024-06609-w.


A Systematic Review of Uremic Toxin Concentrations and Cardiovascular Risk Markers in Pediatric Chronic Kidney Disease.

Dalpathadu H, Salim A, Wade A, Greenway S Toxins (Basel). 2024; 16(8).

PMID: 39195755 PMC: 11358976. DOI: 10.3390/toxins16080345.


Indoxyl Sulfate Contributes to Impaired Height Velocity in (Pre)School Children.

Snauwaert E, De Buyser S, Van Biesen W, Raes A, Glorieux G, Collard L Kidney Int Rep. 2024; 9(6):1674-1683.

PMID: 38899199 PMC: 11184389. DOI: 10.1016/j.ekir.2024.03.021.


Comparison of two methods for dimethylarginines quantification.

Sudova V, Prokop P, Trefil L, Racek J, Rajdl D Pract Lab Med. 2024; 39:e00359.

PMID: 38313812 PMC: 10831080. DOI: 10.1016/j.plabm.2024.e00359.


Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study.

Samaey A, Vazquez-Castellanos J, Caenepeel C, Evenepoel P, Vermeire S, Raes J Pediatr Nephrol. 2023; 39(4):1201-1212.

PMID: 37775582 DOI: 10.1007/s00467-023-06168-6.